Company Introduction
Company Profile
Product Information
Japanese Site


JIMRO's prime mission is to promote health of people worldwide.
JIMRO employees are given an opportunity to improve themselves through engagement in meaningful responsibilities.
The company and employees will continue to grow steadily together.

The human immune system is one of the most fascinating components of the human body. As an example, once a person has contracted measles, such an individual may never develop symptoms of measles again.
Despite striking advances in modern medicine in recent years together with rapid changes in the standard of living and quality of life, we are still being challenged by refractory autoimmune diseases, viral infections and cancers. Fascinated by the human immune system, we became engaged in research since the foundation of Japan Immunoresearch Laboratories Company Limited (JIMRO) in the hope of obtaining further insights into immune disorders and use such knowledge to the challenging disorders.
As part of our response to the existing challenges, we have devoted major emphasis on lymphocytes, monocytes and granulocytes which are major players in immune functions. As a fruit of our endeavours, we developed a therapeutic device, the only one in the world, which selectively adsorbs granulocytes and monocytes / macrophages from the blood. In October 1999, our medical device developed and named Adacolumn received an approval from the Japan Ministry of Health, Labour and Welfare for manufacturing and marketing. At present, Adacolumn is reimbursed for the treatment of ulcerative colitis , Crohn’s disease and pustular psoriasis in Japan. Currently, additional projects in other refractory diseases are in progress in worldwide for expanding these indications of the Adacolumn. We will continue our efforts to develop innovative technologies and therapeutic approaches. Our ultimate goal is to provide effective challenges to a variety of therapeutic approaches including refractory diseases.